Clinical Trial Update: A Research Study To Test How Multiple Doses Of Filgrastim Hospira Works In The Body Of Healthy Study Subjects When Given by Subcutaneous Injection (SC) (Shot) Compared To An Already U.S.-Approved Drug Neupogen® (Amgen) [Phase 1]

View source ↗

Summary

Phase 1 study comparing multiple doses of the filgrastim biosimilar Filgrastim Hospira to the reference product Neupogen in healthy subjects.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neutropenia

Drugs mentioned

• Filgrastim Hospira (filgrastim)
• Neupogen (Filgrastim)

Snippet

Sponsor: Pfizer | Conditions: Neutropenia (Low White Blood Cell Count) | Phase 1 | Status: COMPLETED